Navigation Links
InspireMD Provides Corporate Update, Plans for 2012
Date:1/23/2012

als and Objectives

  • Complete the Master Trial and report results (2H, 2012) at a major interventional cardiology meeting.
  • Initiate and commence enrollment in the FDA Registration trial of MGuard™.
  • Obtain CE Mark approval for MGuard Carotid™ product. 
  • Initiate clinical study for MGuard Carotid™.
  • Expand commercial and manufacturing infrastructure in anticipation of MGuard™ demand, including the hiring of key senior executives.
  • Pursue additional registrations and distribution contracts in new countries.

MASTER Trial Enrollment on Track, Primary Endpoint Data Expected in Third Quarter

The MASTER (MGuard™ for Acute ST Elevation Reperfusion) randomized trial seeks to enroll 432 patients in a two-arm, parallel design study.  The objective is to evaluate the MGuard™ stent compared to commercially-approved BMS or DES products in achieving myocardial reperfusion in primary angioplasty for the treatment of STEMI patients. The primary endpoint is complete ST segment resolution.

Clinical follow-up will continue for one year and important secondary endpoints such as TIMI (Thrombolysis In Myocardial Infarction) flow, myocardial blush grade and MACE will be measured. Additional sub-studies for cardiac MRI and invasive angiography are planned as well. Dr. Gregg Stone, Director of Cardiovascular Research and Education, Columbia University in New York, is the study chairman.

Eli Bar, CTO and Vice President of Research and Development of InspireMD, commented: "We are pleased that enrollment in the MASTER Trial is advancing on schedule and we anticipate completing enrollment in the second quarter of 2012." He added: "The intent of the MASTER Trial is to provide additional supportive data based on a large, multi-national randomized trial."

The MASTER Trial is being conducted in 12 count
'/>"/>

SOURCE InspireMD
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
2. For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System
3. InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative
4. InspireMD Boosts MGuard Production Capacity
5. InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
6. InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference
7. InspireMD Increases Geographic Penetration; MGuard Stent is Now Available in India
8. InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week
9. InspireMD Announces Year-to-Date 2011 Progress
10. InspireMD Broadens Global Distribution Network; Signs Distributor for the Russian Federation
11. Sol J. Barer, Ph.D. Joins InspireMD Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 , Joint research by ... from Biostar , Published in ,Stem Cells Translational ... lifespan through multiple IV administration of Adipose-derived MSC ... expectancy found , Commercialization within 5 years expected ... possibility that adult mesenchymal stem cells (MSCs) may extend ...
(Date:8/27/2015)... , Aug. 27, 2015  The Academy ... Food and Drug Administration,s (FDA,s) draft guidance and ... products and biosimilars, to bear a nonproprietary name ... has been seeking a decision from the FDA ... diverse health care stakeholders urging the agency to ...
(Date:8/27/2015)... According to a new market research report ... Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), ... MarketsandMarkets, the Medical Lifting Sling Market is poised to reach USD ... a CAGR of 11.4 % from 2015 to 2020. ... data T ables and 65 F ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... 2, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced that, ... determination from the NASDAQ Listing Qualifications Panel (the "Panel") ... for an extension to remain listed on The NASDAQ ...
... 2011 Pacira Pharmaceuticals, Inc., (Nasdaq: ... announced that positive results from its Phase 1 ... patients with moderate hepatic impairment, will be presented ... and Therapeutics (ASCPT) 112th Annual Meeting in Dallas, ...
Cached Medicine Technology:Nile Therapeutics Receives Positive NASDAQ Panel Decision 2Nile Therapeutics Receives Positive NASDAQ Panel Decision 3Pacira Pharmaceuticals' EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting 2Pacira Pharmaceuticals' EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting 3
(Date:8/30/2015)... ... August 30, 2015 , ... ... medical devices for the treatment of prostate cancer, has announced the roll-out of ... at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is ... chiropractic field in the military. All too often VA hospitals treat patients with harmful ... to the VA program over a decade ago, the reality is that only 10% ...
(Date:8/29/2015)... ... 29, 2015 , ... People who have heart or lung ... asthma, are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with ... problems (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , ...
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College ... and the student experience as part of the EDUCAUSE - Next Generation Learning Challenges ... , This is the third Breakthrough Models Incubator hosted by EDUCAUSE and ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... Test To Provide Physicians in U.S. and Europe ... , MADISON, N.J., June 2 HemoCue AB, an ... subsidiary of Quest Diagnostics Incorporated (NYSE: DGX ), ... Dynamics Corp (MEC) for the exclusive distribution of the Avie(TM) ...
... NEW YORK, June 2 , ... FOI Documents Through 1991 , ... clinical and post-marketing drug,information, has significantly expanded its coverage ... the launch of the FDA Classic,Collection. This collection contains ...
... June 2 Versus Technology, Inc. (Pink Sheets: VSTI) ... and OR Solutions to Chalmers P. Wylie Veterans Ambulatory ... rules-based real-time location information system (RTLiS) will be installed ... surgery center and clinics. , , The ...
... , , , Approval for ... Pa., June 2 B. Braun Medical Inc. (B. Braun), a ... U.S. Food and Drug Administration (FDA) approval for 2g ... DUPLEX(R) Drug Delivery System . , , (Logo: ...
... screens, researchers say , TUESDAY, June 2 (HealthDay News) -- ... more types of cancer than previously thought, a new study ... successfully used for early detection of colorectal cancer, researchers at ... also good at finding other gastrointestinal cancers, such as those ...
... that could influence the way researchers screen for, treat ... cancer, an aggressive form of the disease. One finding ... "Women with locally advanced breast cancer and their ... mass should not be ignored even if someone has ...
Cached Medicine News:Health News:Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite 2Health News:Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite 3Health News:Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite 4Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 2Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 3Health News:Versus Technology, Inc. Announces Sale of Real-Time Location Information System to the Chalmers P. Wylie Veterans Clinic 2Health News:Versus Technology, Inc. Announces Sale of Real-Time Location Information System to the Chalmers P. Wylie Veterans Clinic 3Health News:B. Braun Anticipates Becoming First to Deliver FDA Approved 2g Cefazolin 2Health News:B. Braun Anticipates Becoming First to Deliver FDA Approved 2g Cefazolin 3Health News:Simple Test Could Detect More Gastrointestinal Cancers 2Health News:I-SPY trial offers key insights into locally advanced breast cancer 2Health News:I-SPY trial offers key insights into locally advanced breast cancer 3
... Gentian violet ink stands ... Millimeter scale ruler printed ... for quick measuring. Flexible, ... both inch and metric ...
Freer elevator, double end, 7 1/4", S/B....
Stainless steel dull finish....
The Ultima 2000 SE is flexible in meeting the needs of both office and operating room use. It is the answer for the clinical practice with a wide range of ophthalmic demands looking for minimal risk ...
Medicine Products: